Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
    • ALXN1840
      • EASL Poster May 2025
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Aug 10, 2023

Monopar Provides Encouraging Camsirubicin Clinical Data Update

Aug 8, 2023

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

Jul 11, 2023

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 21, 2023

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

Jun 14, 2023

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

Jun 1, 2023

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 11, 2023

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Mar 28, 2023

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

Mar 27, 2023

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Mar 23, 2023
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...12
    • About
    • Pipeline
    • Investors
    • Our Team
    • Careers
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
    • Collaborations
    • Publications
    • ALXN1840
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2025 Monopar Therapeutics Inc. All Rights Reserved.